Combined detection of postoperative CA50 CA199 CA242 CEA observation of pancreatic cancer

Combined detection of postoperative CA50 CA199 CA242 CEA observation of pancreatic cancer Combined detection of postoperative CA50 CA199 CA242 CEA observation of pancreatic cancer [Abstract] Objective To observe the serum of patients with pancreatic cancer carbohydrate antigen 50 (CA50), carbohydrate antigen 199 (CA199), carbohydrate antigen 242 (CA242), carcinoembryonic antigen CEA recurrence of pancreatic cancer the clinical value of diagnosis . Methods chemiluminescence and enzyme-linked immunosorbent assay, were detected in 41 cases of pancreatic cancer patients after serum CA50, CA199, CA242, CEA levels, and continuous monitoring. Results 34 cases of pancreatic cancer recurrence CA50, CA199, CA242, CEA was elevated in 25 cases (73.5%), 28 patients (82.4%), 27 cases (79.4%), CEA25 cases (73.5%), 4 single tumor marker levels were higher than those without recurrence group , and the differences were statistically significant (P <0.01). Conclusion Postoperative joint determination of CA199, CA50, CEA, CA242 could prompt early postoperative recurrence of pancreatic cancer, increase the sensitivity of diagnosis of pancreatic cancer recurrence. 1 [Keywords:] CA199 CA50 CEA CA242 tumor marker of pancreatic cancer High rate of clinical recurrence of pancreatic cancer, so early diagnosis of recurrence of pancreatic cancer is very important, and the use of a single item sensitivity and specificity of detection is not ideal. We used serum tumor-related substances carbohydrate antigen 199 (carbohydrate antigen199 , CA199) and carbohydrate antigen, carbohydrate antigen 50 (carbohydrate antigen50, CA50), CEA (carcinoembryonic antigen CEA), carbohydrate antigen 242 (carbohydrate antigen 242, CA242) combination of methods to detect serum levels after to investigate the clinical recurrence of pancreatic cancer diagnosis. 1 Materials and methods 1.1 Materials 41 cases I, ?, after curative resection of pancreatic cancer patients are forward-looking dynamic observation of the object, according to Japan Pancreas Society stage disease (Japan Pancreas Society will be divided into four phases: ? ? of: tumor diameter less than 2cm, No regional lymph node metastasis, no infiltration of pancreatic capsule, retroperitoneal, portal vein, superior mesenteric vein and splenic vein, ? ? period: tumor diameter 2.1 ~ 4.0cm, close to the tumor of the lymph 2 node metastasis, pancreatic capsule, retroperitoneal, and previous vascular may be transferred, ? ? period: tumor diameter 4.1 ~ 6cm, 1 Station and 3 stations of lymph node metastasis, pancreatic capsule and peritoneum after the invasion, ? ? of: tumor diameter greater than 6.1cm, 3 lymph node stations transfer, invading into adjacent organs, retroperitoneal, and extensive infiltration of the aforementioned vein.): I of 15 cases, ? in 26 cases, including 23 males and 18 females, aged 42-71 years old I .34 cases of recurrence in patients 11 cases, ? in 23 patients, 26 males, 8 females, age at diagnosis of recurrence after 42-69 years of age. 1.2 Methods 1.2.1 Monitoring plan and follow-up after curative resection in patients with pancreatic cancer six weeks of fasting blood pumping test CA50, CA199, CA242, CEA examination for the first time, including physical examination, B-, and then inspected once every 3 months, after test results If you find no decline or increase during the period, the second re-examination within a month as higher recurrence was highly suspected, such as suspected recurrence, further to take other measures .26-month 3 follow-up 3-26 months after the first relapse to increase included in recurrent group. 1.2.2 Detection Methods chemiluminescence detection CA50, CA199, CEA, enzyme-linked immunosorbent assay CA242.CA50, CA199, CA242 threshold were 30,35,20 U / mL, CEA determination threshold smokers 10ng / mL, non-smokers 5ng/mL. 1.2.3 Statistical Methods Measurement t test was used to compare data on the sensitivity of the individual and the group made after the X2 test 2 Results 2.1 during the observation period, 34 cases of recurrence, the recurrence of 34 patients, CA50, CA199, CA242, CEA was elevated in 25 cases (73.5%), 28 patients (82.4%), 27 cases (79.4%), CEA25 cases (73.5%). confirmed that began to rise before those who were 5 patients (20%), 6 cases (21.4%), 5 cases (18.5%), 6 patients (23.1%). 7 patients did not relapse group of four tumors were no higher. no recurrence group and recurrence of pancreatic cancer serum indexes shown in table 4. Table without recurrence group and recurrence group 4 3 Comparative (x +-s) (u / ml) Group the number of cases Ca50CA199CA242CEA Recurrent group 34,108.1 + -49.1462.4 + -186.152.8 + -28.831.6 + -12.4 Without recurrence group was 73.5 + -2.819.5 + -7.17.4 + -4.22.3 + -6.8 2.2 Detection of individual and combined sensitivity of diagnosis of pancreatic cancer recurrence During the individual tumor markers in the diagnosis of pancreatic cancer recurrence, CA199 highest sensitivity, at 82.4%, CA242 was (79.4%), CA50 is 73.5%, CEA 73.5%. Joint detection (refer to any one of four test Index positive) positive rate was 95.1% (39/41), can significantly improve the diagnostic sensitivity. 3 Discussion In recent years, the incidence of pancreatic cancer has continued to rise, treatment and prognosis of pancreatic cancer are not ideal, clinically diagnosed patients are often already in the late stage, only 10% of patients can be radical surgery [1]. How to improve the operation early diagnosis of recurrence and metastasis after it is integrated to further enhance the efficacy of pancreatic cancer the key. reposted elsewhere in the paper for free download ..com 5 CA50 is a sialic acid glycoprotein and sialic acid as the main component of the sugar glucose and lipid antigen .1983 Lindholm and others in the system with colon cancer monoclonal antibody CA50 acquired a tumor-associated antigen in neural lipid glycosides CA50, this antigen in the form of fat or lipoproteins present in the cell membrane, glycolipids belonging to the sheath markers. is a more common cancer associated antigen. that in normal cells into malignant cells when the synthesis, reflects the dynamic process of malignant cells. In addition CA50 content with tumor invasion and metastasis are closely related, so the serum levels of CA50 pancreas prediction of metastasis and recurrence of the observation is a good reference. CA50 Another advantage is that because it does not have sialic acid epitope on o-fucose, it can not display the expression of CA199 in pancreatic cancer patients [ 2]. Our data show that pancreatic cancer recurrence after radical group determined the value of 108.1 + -49.1u/ml quite different with and without recurrence group, the positive rate was 73.5% recurrence group. CA199 is a tumor associated antigen oligosaccharides 6 was Koprowski 1979 ANNUAL mice immunized with colon cancer cell lines and tumors and bone bits from 1116Ns199 hybrid monoclonal antibody [3] .1983 Delvillano such as in pancreatic cancer markers used in clinical [4]. CA199 in the diagnosis and prognosis of patients with pancreatic cancer is the most valuable aspects of tumor markers can be used to reflect the prognosis, monitoring the recurrence, but the sensitivity of early diagnosis of pancreatic cancer recurrence still not satisfactory. has been reported in patients monitored during follow-up CA199 levels in abnormal imaging studies before the onset of clinical signs before or prompt tumor recurrence or distant metastasis, recurrence of about 88% of CA199 levels were significantly rise high [5]. In this study, after curative resection of pancreatic cancer patients to monitor recurrence in patients with CA199 levels were significantly higher than normal, the result is 462.4 + -186.1u/ml, the diagnosis of postoperative recurrence of pancreatic cancer, CA199 sensitivity the highest positive rate was 82.4%, it is worth noting that there are 6 cases of elevated CA199 in patients with no obvious clinical symptoms caused by abnormal markers of vigilance and the final diagnosis. 7 The chemical properties of CA242 for the sialylated glycolipid antigens. Research data shows that the expression of CA242 and pancreatic cancer, there is a certain relationship between the development of [6]. Tumor markers in pancreatic cancer treatment is effective, the concentration decreased to normal or even, or increased as the disease progresses [7]. In this study, recurrence after curative resection of pancreatic cancer serum CA242 test were significantly higher than group without recurrence, after curative resection of pancreatic cancer is not recurrent group CA242 returned to normal, CA242 increased the relapse group. CEA is intestinal adenocarcinoma and fetal intestine in a fetal antigen. CEA in this set of data, the positive rate of recurrence of pancreatic cancer was 73.5%, significantly higher than recurrence group, can be used as recurrence and metastasis of pancreatic cancer diagnostic indicators . In summary, the simultaneous analysis of serum C1A99, CA242, CEA, CA50 recurrence of pancreatic cancer is significant. CA199 positive rate is higher than CA50, CEA and CA242. Joint detection can significantly improve the detection 8 sensitivity and negative predictive value, and reduce the risk of missed diagnosis, the diagnosis of postoperative recurrence in pancreatic cancer has some clinical value, for the treatment to help. References [1] Le-Zhi Zhang, RESTRAINT. Pancreatic quantitative determination of serum CA242 and its significance [J]. Pancreatic Diseases, 2002,2 (1) :20-21. [2] Equal Interval, Peng Huang. CA199, CA50 and CEA combined detection in the diagnosis of pancreatic cancer [J]. Xianning College (Medical Sciences), 2007,21 (2) :119-121. [3] Koprowski H, Herlyn M, Seplewski Z, et al.Colrectai Carciamna.antigens detected by hybridoma antibodies Somat Cell Genet 1979; 5:957. [4] Sperti C, Pasquali C, Guolo PM et al.Serum tumor markers.and cyst fluid analysis are useful for the diagnosis of pancreatic cystic tumors.Cancer, 1996; 78 (2): 237. [5] Lai Jianping, Qin Jie, Ling Shan. Tumor Markers for 9 Differentiation of pancreatic cancer diagnosis and the value of postoperative follow-up [J]. Radiation Immunology, 2005,16 (6) :375-376. [6] Zhang Min. 4 serum tumor markers for diagnosis of pancreatic cancer [J]. Occupation and Health, 2005,7 (21) 1007-1008. [7] Shen Kui, Zhong Shou first, Chang San Road. Pancreatic surgery [M]. Beijing: People Health Press, 2000:202. Links ..com download the free paper 10